Healthcare provider profile · identity verified

Deborah A Kelley, PAC

Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · TRINIDAD, TX · NPI 1205884863

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Deborah A Kelley, PAC received $30.41 in general payments during 2025 across 1 reported records.

Becton, Dickinson and Company accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$30.41

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Becton, Dickinson and Company Unresolved — no canonical attribution shown $30.41100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$30.411

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Magic3 Go Intermittent Urinary Catheter
Normalized: magic3 go intermittent urinary catheter
Device Becton, Dickinson and Company $30.41 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Levothyroxine SodiumLevothyroxine Sodium23473
Rosuvastatin CalciumRosuvastatin Calcium18066
GabapentinGabapentin15354
LisinoprilLisinopril12741
Atorvastatin CalciumAtorvastatin Calcium10935
HydrochlorothiazideHydrochlorothiazide9536
Amlodipine BesylateAmlodipine Besylate9331
Losartan PotassiumLosartan Potassium9231
PrednisonePrednisone8761
Tamsulosin HclTamsulosin Hcl8734
Tramadol HclTramadol Hcl8330
EzetimibeEzetimibe8131
Metoprolol SuccinateMetoprolol Succinate7028
OmeprazoleOmeprazole6925
Escitalopram OxalateEscitalopram Oxalate6824
Metformin HclMetformin Hcl6816
Alendronate SodiumAlendronate Sodium6528
Pantoprazole SodiumPantoprazole Sodium6129
Potassium ChloridePotassium Chloride6126
EliquisApixaban5314
Pravastatin SodiumPravastatin Sodium5317
AzithromycinAzithromycin5242
JardianceEmpagliflozin4916
Montelukast SodiumMontelukast Sodium4819
OzempicSemaglutide4612
Metformin Hcl ErMetformin Hcl4519
FurosemideFurosemide4321
Acetaminophen-CodeineAcetaminophen With Codeine41suppressed
CarvedilolCarvedilol4112
ClopidogrelClopidogrel Bisulfate3715
ValsartanValsartan3714
GlimepirideGlimepiride3515
MeloxicamMeloxicam3513
FenofibrateFenofibrate3414
Albuterol Sulfate HfaAlbuterol Sulfate3320
Sertraline HclSertraline Hcl32suppressed
AlprazolamAlprazolam31suppressed
FluconazoleFluconazole3118
Ciprofloxacin HclCiprofloxacin Hcl3019
Amitriptyline HclAmitriptyline Hcl29suppressed
TrulicityDulaglutide29suppressed
SynthroidLevothyroxine Sodium27suppressed
Duloxetine HclDuloxetine Hcl26suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25suppressed
SpironolactoneSpironolactone24suppressed
Trazodone HclTrazodone Hcl24suppressed
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23suppressed
MupirocinMupirocin2316
SimvastatinSimvastatin23suppressed
Zolpidem TartrateZolpidem Tartrate23suppressed
AtenololAtenolol22suppressed
ProliaDenosumab2013
EstradiolEstradiol19suppressed
FenofibrateFenofibrate Nanocrystallized19suppressed
Ondansetron HclOndansetron Hcl1911
Ondansetron OdtOndansetron1916
AllopurinolAllopurinol18suppressed
Fluticasone PropionateFluticasone Propionate18suppressed
Ipratropium BromideIpratropium Bromide1814
MounjaroTirzepatide18suppressed
Tizanidine HclTizanidine Hcl17suppressed
CelecoxibCelecoxib16suppressed
Hydralazine HclHydralazine Hcl16suppressed
Testosterone CypionateTestosterone Cypionate16suppressed
TradjentaLinagliptin16suppressed
XareltoRivaroxaban16suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl15suppressed
VascepaIcosapent Ethyl15suppressed
PregabalinPregabalin14suppressed
Buspirone HclBuspirone Hcl13suppressed
CephalexinCephalexin1312
Clindamycin HclClindamycin Hcl1311
Cyclobenzaprine HclCyclobenzaprine Hcl13suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav1211
Esomeprazole MagnesiumEsomeprazole Magnesium12suppressed
FarxigaDapagliflozin Propanediol12suppressed
Felodipine ErFelodipine12suppressed
LevemirInsulin Detemir12suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide12suppressed
Metoprolol TartrateMetoprolol Tartrate12suppressed
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst1212
Venlafaxine Hcl ErVenlafaxine Hcl12suppressed
Vitamin D2Ergocalciferol (Vitamin D2)12suppressed
Clonidine HclClonidine Hcl11suppressed
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)11suppressed
Fluoxetine HclFluoxetine Hcl11suppressed
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $30.41 · 1 records Becton, Dickinson and Company Magic3 Go Intermittent Urinary Catheter
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error